- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.01. | NeuroSense granted U.S. patent for treatment of Alzheimer's disease | 1 | Seeking Alpha | ||
| 06.01. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 22.12.25 | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 22.12.25 | NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study | 385 | PR Newswire | Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026
CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense")... ► Artikel lesen | |
| 04.12.25 | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.11.25 | NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS | 393 | PR Newswire | CAMBRIDGE, Mass., Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing... ► Artikel lesen | |
| 21.11.25 | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.10.25 | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.09.25 | Halberd Corp.: Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment | 4 | GlobeNewswire (USA) | ||
| 25.09.25 | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.09.25 | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.09.25 | NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons | 197 | PR Newswire | Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile
CAMBRIDGE, Mass., Sept. 10... ► Artikel lesen | |
| 08.09.25 | RECIPHARM AB: Recipharm partners with NeuroSense Therapeutics to advance ALS therapy PrimeC toward Phase 3 trials | 3 | Cision News | ||
| 04.09.25 | NeuroSense Therapeutics announces $500,000 private placement | 8 | Seeking Alpha | ||
| 02.09.25 | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 20.08.25 | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.08.25 | NeuroSense Therapeutics Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 01.08.25 | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 24.04.25 | NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update | 230 | PR Newswire | Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about... ► Artikel lesen | |
| 09.04.25 | NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment | 361 | PR Newswire | New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS.
CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARDIOL THERAPEUTICS | 0,820 | -0,61 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million | Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| QIAGEN | 44,790 | -1,53 % | Aktien Frankfurt Ausblick: Kleines Minus im Dax erwartet - Qiagen weiter stark | FRANKFURT (dpa-AFX) - Der deutsche Aktienmarkt bleibt auch am Mittwoch im Korrekturmodus. Nachdem sich zuletzt die Unsicherheit wegen der Zoll-Politik von US-Präsident Donald Trump wieder verstärkt... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 316,00 | +0,40 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines | ||
| BIONTECH | 96,00 | -3,27 % | BioNTech Aktie: Goldman Sachs mit Ritterschlag! Hohes Kurspotential! | © Foto: Foto von Ricardo Cruz auf UnsplashTolle News für die Mainzer. Goldman Sachs stuft BioNTech höher ein und setzt ein neues Kursziel. Das ist mehr als nur eine technische Anpassung. Es ist ein... ► Artikel lesen | |
| EVOTEC | 6,322 | +2,50 % | Evotec, A.H.T. Syngas Technology, Deutsche Telekom: Drei Aktien vor dem entscheidenden Wendepunkt? | Deutschlands Wirtschaft steht am Scheideweg. Die alten Stärken bröckeln, doch genau das eröffnet Chancen für Unternehmen, die sich strategisch neu ausrichten. Nicht einfache Anpassung, sondern ein fundamentaler... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,100 | -5,21 % | Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway | ||
| STRUCTURE THERAPEUTICS | 88,43 | -1,21 % | Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It | ||
| AVIDITY BIOSCIENCES | 72,55 | -0,12 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,540 | -1,30 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| ERASCA | 9,995 | -4,81 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,130 | -0,96 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 71,08 | -1,48 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,720 | -1,07 % | Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive | ||
| ALUMIS | 25,870 | -0,50 % | Chardan Capital initiates coverage on Alumis stock with Buy rating | ||
| GRI BIO | 5,150 | -7,21 % | GRI Bio, Inc.: GRI Bio Announces Reverse Stock Split | GRI's common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company")... ► Artikel lesen |
NEUROSENSE THERAPEUTICS LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,020 (-2,78 %) liegt der Kurs bei 0,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROSENSE THERAPEUTICS LTD finden Sie auf Wallstreet Online.